Table 4.
Adjusted overall survival followinbg neoadjuvant chemotherapy in N2–N3 Breast Cancer (N=2375).
| HR (95% Cl) | P-Value | Overall P-Value | |
|---|---|---|---|
| Axillary Surgery Group | <.001 | ||
| SLNB (1–5 LNs) | REF | ||
| ALND (10+ LNs) | 0.604 (0.458–0.797) | <0.001 | |
| Pathologic Response | <0.001 | ||
| No Complete Response | REF | ||
| Complete Response | 0.374 (0.282–0.495) | <0.001 | |
| Age (Years) | 0.992 (0.983–1.001) | 0.06 | 0.06 |
| Race | 0.03 | ||
| White | REF | ||
| Black | 1.198 (0.959–1.497) | 0.11 | |
| Other | 0.525 (0.273–1.012) | 0.05 | |
| Charlson/Deyo Score | 0.04 | ||
| 0 | REF | ||
| 1 | 1.371 (1.020–1.843) | 0.04 | |
| ≥2 | 1.825 (0.872–3.819) | 0.11 | |
| Income Level | 0.97 | ||
| ≥$35,000 | REF | ||
| <$35,000 | 0.995 (0.787–1.258) | 0.97 | |
| Insurance Type | 0.04 | ||
| Private | REF | ||
| Government | 1.189 (0.945–1.497) | 0.14 | |
| Not Insured | 1.573 (1.070–2.313) | 0.02 | |
| Education Level | 0.15 | ||
| >80% High School Graduation Rate | REF | ||
| ≤80% High School Graduation Rate | 1.173 (0.944–1.459) | 0.15 | |
| Facility Location | 0.69 | ||
| South | REF | ||
| Midwest | 1.104 (0.877–1.389) | 0.40 | |
| Northeast | 0.938 (0.715–1.228) | 0.64 | |
| West | 1.025 (0.731–1.439) | 0.88 | |
| Facility Type | 0.06 | ||
| Academic | REF | ||
| Community | 1.521 (1.112–2.082) | 0.009 | |
| Comprehensive | 1.080 (0.871–1.339) | 0.48 | |
| Integrated Network | 1.235 (0.847–1.802) | 0.27 | |
| ER Status | 0.37 | ||
| Positive | 0.800 (0.491–1.301) | 0.37 | |
| Negative | REF | ||
| PR Status | <0.001 | ||
| Positive | 0.443 (0.312–0.628) | <0.001 | |
| Negative | REF | ||
| HER2 Status* | <0.001 | ||
| Positive | 0.559 (0.432–0.724) | <0.001 | |
| Negative | REF | ||
| Clinical N-Stage | 0.14 | ||
| 2 | REF | ||
| 3 | 1.186 (0.944–1.490) | 0.14 | |
| Clinical T-Stage | 0.82 | ||
| 1 | REF | ||
| 2 | 1.022 (0.735–1.422) | 0.90 | |
| 3 | 1.085 (0.771–1.527) | 0.64 | |
| Grade | <0.001 | ||
| 1 | REF | ||
| 2 | 1.511 (0.762–2.996) | 0.24 | |
| 3 | 2.530 (1.272–5.030) | 0.008 | |
| Histology | 0.35 | ||
| Invasive Ductal | REF | ||
| Invasive Lobular | 0.876 (0.537–1.431) | 0.60 | |
| Other Invasive | 0.587 (0.270–1.274) | 0.18 | |
| Surgery Type | 0.01 | ||
| Mastectomy | REF | ||
| Lumpectomy | 0.720 (0.555–0.933) | 0.01 | |
| # Positive LNs | 1.055 (1.041–1.070) | <0.001 | <0.001 |
| Radiation Use | 0.722 (0.550–0.949) | 0.02 | 0.02 |
| Endocrine Therapy Use | 0.727 (0.480–1.100) | 0.13 | 0.13 |
*
HER2 status is frequently missing in this database, hence the highly reduced sample size included in this model.